This is a study to assess the safety and tolerability of subcutaneously administered REGN1033 (SAR391786) in healthy volunteers.
Latest Information Update: 12 Jun 2014
At a glance
- Drugs Trevogrumab (Primary)
- Indications Muscular atrophy
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 12 Jun 2014 New trial record